Remission maintenance of adult acute lymphoblastic leukemia

James O. Armitage, C. Patrick Burns

Research output: Contribution to journalArticlepeer-review

14 Scopus citations


This report describes the results of a study of central nervous system (CNS) prophylaxis and combination chemotherapy for the maintenance of remission in adult acute lymphoblastic leukemia. Adults with acute lymphoblastic leukemia who achieved complete remission were treated with 2,400 rads cranial irradiation and intrathecal methotrexate for CNS prophylaxis followed by continuation systemic chemotherapy with oral methotrexate, 6‐mercaptopurine and cyclophosphamide. There were no CNS relapses following treatment. One‐half of the patients relapsed within 11 months, with 5 patients remaining in remission for 27+ to 31+ months. The toxicity was acceptable with no treatment‐related deaths. This regimen is capable of producing long remissions in a significant proportion of adults with acute lymphoblastic leukemia and appears to be effective in reducing the incidence of CNS relapse. It has the additional advantage of ease of administration and can be largely administered in the community.

Original languageEnglish (US)
Pages (from-to)53-58
Number of pages6
JournalMedical and Pediatric Oncology
Issue number1
StatePublished - 1977
Externally publishedYes


  • acute lymphoblastic leukemia
  • adult CNS leukemia

ASJC Scopus subject areas

  • Pediatrics, Perinatology, and Child Health
  • Oncology
  • Cancer Research


Dive into the research topics of 'Remission maintenance of adult acute lymphoblastic leukemia'. Together they form a unique fingerprint.

Cite this